Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
Korean Journal of Ophthalmology
;
: 355-357, 2011.
Article
Dans Anglais
| WPRIM
| ID: wpr-15768
ABSTRACT
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pipéridines
/
Quinazolines
/
Acuité visuelle
/
Études de suivi
/
Carcinome pulmonaire non à petites cellules
/
Cornée
/
Maladies de la cornée
/
Microscopie acoustique
/
Diagnostic différentiel
/
Relation dose-effet des médicaments
Type d'étude:
Etude diagnostique
/
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Adulte
/
Femelle
/
Humains
langue:
Anglais
Texte intégral:
Korean Journal of Ophthalmology
Année:
2011
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS